Literature DB >> 8121684

Exogenous heparin, topically administered, aids the remodelling of connective tissue in the healing of experimental tympanic membrane perforations.

S Hellström1, O Spandow.   

Abstract

Heparin, in concentrations of 250, 2,500 and 25,000 IU, was applied topically to the edge of tympanic membrane (TM) perforations, standardized in size, once daily until the perforation had closed. At 2 months, the animals were killed and the TMs subjected to otomicroscopic and light microscopic studies. The day that closure of the TM perforations was complete (median 8 days) was the same for the various heparin groups as for the sterile water-treated controls. However, regarding opacity of the healed TM area, heparin affected the TM in a dose-dependent manner. The TMs that had been subjected to the highest concentration of heparin were the most transparent and showed the least sclerosis. When compared for thickness, the TMs treated with the higher concentration of heparin were considerably thinner than those treated with the lower concentration. The sterile water-treated controls were all thicker than the heparin-treated TMs. It is inferred that glycosaminoglycan heparin improves the quality of the healed area of TM perforations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8121684     DOI: 10.1159/000276607

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  2 in total

1.  Inhibition of the development of myringosclerosis by local administration of fenspiride, an anti-inflammatory drug.

Authors:  C Mattsson; S Hellström
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

2.  The impact of topical and systemic enoxaparin sodium use on traumatic tympanic membrane perforation and myringosclerosis.

Authors:  Arif Bilge; Akif Gunes; Muharrem Dagli; F Fulya Koybasioglu; Ali Guvey
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-21       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.